Chargement en cours...
The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss...
Enregistré dans:
| Publié dans: | Drug Des Devel Ther |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6709822/ https://ncbi.nlm.nih.gov/pubmed/31686781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S166765 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|